At NKore, we are racing to bring forward a breakthrough, non-toxic immunotherapy for patients with recurrent, incurable leukemia—people who have exhausted every option and can’t survive more toxic treatments. Backed by 35 years of research, our therapy supercharges the body’s natural killer (NK) cells to attack cancer at its source, showing remarkable results: rapid symptom relief, major tumor shrinkage, and restored immune function, sometimes within days. To keep momentum, we urgently need funding to treat 30 additional patients under compassionate use in Cancun, Mexico, while completing the critical studies required for our FDA submission this year. These funds will power large-scale cell manufacturing and the clinical operations needed to deliver care and prove this therapy’s impact. Without this support, a life-saving treatment could be lost to the “Valley of Death,” leaving countless patients without hope and setting back years of pioneering research.
SHARE:
For patients battling recurrent, incurable leukemia, today’s treatments—like chemotherapy, radiation, and even some targeted drugs—often come at a steep cost. These approaches can severely damage the immune system, leaving patients weaker and more vulnerable at a time when they need their defenses the most. Many run out of viable options, facing a future with little hope.
Our work is different. Backed by over 35 years of research, our lead scientist, Dr. Anahid Jewett, has uncovered a critical insight: cancer often begins when the body’s Natural Killer (NK) cells—known as the “generals” of the immune system’s army—fail. These specialized cells are uniquely equipped to detect and destroy cancer stem cells, which exist in all of us. When NK cells falter, these stem cells can escape detection, grow, and mutate into full-blown cancer.
We’ve developed a groundbreaking approach to fix this. By taking healthy donor NK cells and “supercharging” them through our proprietary process, we can restore and strengthen a patient’s immune defenses. These enhanced NK cells can then seek out and destroy cancer at its root—without the devastating side effects of traditional therapies. Our treatment can work on its own or alongside existing treatments, often at lower, less toxic doses.
The early results have been nothing short of remarkable. In studies with more than 350 humanized mice, we’ve seen significant cancer regression—including in leukemia. In our first four patients, who collectively received ten doses, we’ve observed early signs of cancer suppression, restored immune function, and rapid improvements in how patients feel—sometimes within a day of treatment.
Take our first patient as an example. Diagnosed with incurable chronic lymphocytic leukemia (CLL), he came to us exhausted and in pain. After three years of treatment at Mayo Clinic, his cancer burden had never dropped below 20%, and his chest was filled with tumors. On the very day of his first NK cell infusion—despite receiving an extremely low dose, just a fraction of what typical cell therapies use—he began to feel better. By the next day, most of his symptoms were gone. By day 58, 75% of his cancer had disappeared, and his tumors had shrunk by up to 70%.
Months later, a second, slightly higher dose brought his cancer down to just 0.23%. Today, the tumors in his chest are gone, his cancer is nearly undetectable, and he’s back to living his life—out of retirement, active, and feeling better than he has in years.
This is more than treatment—it’s hope. Our mission is to bring this breakthrough to every patient who needs it, offering a safer, more effective way to fight leukemia and rebuild the immune system so people can truly heal.
We’re seeking funding to expand our ability to treat more patients while moving closer to bringing this breakthrough therapy to the U.S. market. With your support, we can treat up to 30 additional patients in Cancun, Mexico, under compassionate use, giving more people access to a treatment that is already changing lives.
At the same time, these funds will help us complete the vital preclinical studies and data analysis needed for our FDA pre-IND submission. Our aim is to file with the FDA by the end of this year so we can begin treating patients in the U.S. as early as 2026.
The funds raised through this campaign will directly fuel two critical needs, ensuring we can treat more patients quickly and effectively:
Cell Therapy Manufacturing – $200,000
To produce multiple manufacturing runs, creating enough therapy to meet the needs of patients waiting for treatment.
Clinical Operations Team – $50,000
To bring on specialized staff to oversee patient intake and manage the treatment process, ensuring every patient receives seamless care.
Together, these investments will allow us to scale our efforts, treat more patients in need, and keep moving this life-changing therapy toward broader availability.
To reach this next critical milestone, we’ve already put several key pieces in place:
Clinical Infrastructure – Established in Cancun, Mexico, where we’ve treated multiple patients under palliative care with highly encouraging results.
Proven Scientific Leadership – A seasoned team with deep experience in advancing therapies through FDA approval.
Regulatory Readiness – A fully assembled FDA submission team prepared to file our application.
Operational Excellence – A core team with decades of expertise in biotech, immunotherapy, and scaling early-stage companies.
Investor Momentum – Three potential institutional investors currently in due diligence.
Now, we’re inviting the broader community to help us bridge this final stage—so we can deliver our breakthrough therapy to more patients who urgently need it.
If our technology were to vanish into the “Valley of Death,” the world would lose far more than just another experimental therapy. We would lose a groundbreaking, non-toxic immunotherapy with the potential to save countless lives.
Our approach directly addresses one of cancer’s most persistent challenges: the failure of natural killer (NK) cells—the body’s first line of defense—to stop cancer stem cells from spreading and recurring. By restoring and supercharging these critical cells, our therapy can suppress cancer and rebuild the immune system, all without the devastating side effects of conventional treatments.
For patients who have run out of options or cannot endure more toxic therapies, this treatment offers something precious: genuine hope. If lost, years of pioneering research would be set back, and countless patients and families would be denied access to a safer, more humane path to healing. The cost—in lives, suffering, and stalled innovation—would be incalculable.
CEO
Jamie Grooms is a prominent figure in the biotechnology sector, recognized for his extensive experience and contributions to the industry. Grooms has also been the CEO of Axogen, Inc., and the Founding CEO of Regeneration Technologies, where he played a crucial role in advancing the companies’ missions within the biotech field. His expertise encompasses various aspects of biotechnology, particularly in the commercialization processes that drive innovation and growth in the sector. His leadership and entrepreneurial spirit have made him a respected figure among peers in the industry.
Cheif Operating Officer
Courtney is a seasoned biopharma executive with 25 years of experience in Oncology and Rare Disease. She has led programs across small molecules, AAV gene therapies, and RNA-targeted therapies from discovery to clinic. At Decibel Therapeutics, she led gene therapy development and a key partnership with Regeneron. At Solid Biosciences, she advanced therapies on accelerated paths. Known for strategic clarity and operational rigor, Courtney excels at building high-performing teams and translating science into impactful therapies.
Co-Founder & Cheif Communitcations Officer
Tracy Ryan has been a marketing executive for over 30 years. She founded and ran several successful businesses in multiple industry segments, and has raised millions in capital raises. Since 2013, she has been committed to finding a cure for her daughter’s pediatric brain tumor. Tracy’s a public figure, globally known cancer advocate, sits on the board of a top pediatric cancer hospital, and her family story has been documented by Netflix, National Geographic and beyond. She is very active in the political arena, has visited the White House on many occasions, speaks yearly on Capitol Hill, and is in regular contact with the Cancer Moonshot Team.
